Recent Press Releases

Perrigo Company plc To Acquire Omega Pharma NV For EUR 3.6 Billion Creating A Top Five Global OTC Company

Perrigo Company plc To Acquire Omega Pharma NV For EUR 3.6 Billion Creating A Top Five Global OTC Company - Accelerates Perrigo's stated strategy to expand internationally and leverage its...

ASTRAZENECA TO DIVEST MYALEPT TO AEGERION

ASTRAZENECA TO DIVEST MYALEPT TO AEGERION 6 November 2014 AstraZeneca today announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™...

Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps

Extensive review and analysis of research data completed Final stage to focus on planned in-field use studies Best Management Practices and Certification Program adopted FDA approval of...

Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015

Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 DUBLIN, Nov. 5, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced...

Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19

Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 - Increases Second Half Non-GAAP EPS Forecast to $6.60-$6.70 - - 158% Increase in Third...

Endo Reports Third Quarter Financial Results

Endo Reports Third Quarter Financial Results Total quarterly revenues of $764 million, reported diluted (GAAP) loss per share of $1.64 and adjusted diluted EPS of $1.15. - Strong financial results...

MERCK: EXECUTIVE BOARD MEMBER OSCHMANN ELECTED PRESIDENT OF IFPMA

MERCK: EXECUTIVE BOARD MEMBER OSCHMANN ELECTED PRESIDENT OF IFPMA Presidency at IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) under overarching theme of...

Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update – Strong LINZESS® (linaclotide) demand: total prescription growth of 22% and sequential U.S. net product sales growth of...

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

Study Failed to Meet Secondary Endpoint of Overall Survival

THOUSAND OAKS, Calif., Nov.

Abbott to Present at Credit Suisse 2014 Healthcare Conference

ABBOTT PARK, Ill., Nov.

Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 4, 2014

Regeneron Reports Third Quarter 2014 Financial and Operating Results

TARRYTOWN, N.Y., Nov. 4, 2014 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2014 and provided an update on development programs....

RECKITT BENCKISER PHARMACEUTICALS INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

RECKITT BENCKISER PHARMACEUTICALS INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER November 4, 2014 – Richmond, Va. – Reckitt Benckiser Pharmaceuticals Inc., a global specialty...

Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx

CARLSBAD, Calif., Nov. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.

Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, November 3, 2014

Takeda Announces Appointment of Marc Princen as President of the EUCAN Business Unit

Osaka, Japan, November 1, 2014 --- Takeda Pharmaceutical Company Limited announced today that Marc Princen joined Takeda Pharmaceuticals International GmbH as Corporate Officer and President of the...

MSF responds to BMS access plans for hepatitis C drug daclatasvir

US pharmaceutical company Bristol-Myers Squibb (BMS) quietly announced late Friday its strategy plans for access to daclatasvir, one of the new direct-acting antiviral (DAA) drugs used to treat...

HCV Developing World Strategy

Bristol-Myers Squibb recognizes the significant public health challenge that hepatitis C (HCV) presents worldwide, including the substantial burden of the disease in the developing world. With more...

Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results

Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a...

Almirall Completes Deal With AstraZeneca in Respiratory Disease

Barcelona, 3rd November 2014 Almirall today announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall's respiratory franchise...